PT2812431T - Pepmixes para gerar ctls multivirais com larga especifidade - Google Patents
Pepmixes para gerar ctls multivirais com larga especifidadeInfo
- Publication number
- PT2812431T PT2812431T PT137465241T PT13746524T PT2812431T PT 2812431 T PT2812431 T PT 2812431T PT 137465241 T PT137465241 T PT 137465241T PT 13746524 T PT13746524 T PT 13746524T PT 2812431 T PT2812431 T PT 2812431T
- Authority
- PT
- Portugal
- Prior art keywords
- multiviral
- pepmixes
- ctls
- generate
- broad specificity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/11—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
- C07K14/135—Respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261596875P | 2012-02-09 | 2012-02-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2812431T true PT2812431T (pt) | 2019-10-18 |
Family
ID=48948057
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT137465241T PT2812431T (pt) | 2012-02-09 | 2013-02-08 | Pepmixes para gerar ctls multivirais com larga especifidade |
PT191782358T PT3591047T (pt) | 2012-02-09 | 2013-02-08 | Pepmixes para gerar ctls multivirais com larga especifidade |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT191782358T PT3591047T (pt) | 2012-02-09 | 2013-02-08 | Pepmixes para gerar ctls multivirais com larga especifidade |
Country Status (9)
Country | Link |
---|---|
US (4) | US20150010519A1 (pt) |
EP (3) | EP3591047B1 (pt) |
DK (2) | DK3591047T3 (pt) |
ES (2) | ES2928851T3 (pt) |
HR (1) | HRP20221303T1 (pt) |
HU (1) | HUE060369T2 (pt) |
PL (2) | PL3591047T3 (pt) |
PT (2) | PT2812431T (pt) |
WO (1) | WO2013119947A1 (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102625832A (zh) | 2009-08-24 | 2012-08-01 | 贝勒医学院 | 产生对多种肿瘤抗原或多种病毒特异的ctl细胞系 |
GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
JP6081483B2 (ja) | 2011-12-12 | 2017-02-15 | セル・メディカ・リミテッド | T細胞を増殖させるプロセス |
HUE060369T2 (hu) | 2012-02-09 | 2023-02-28 | Baylor College Medicine | Peptidkeverékek széles spektrumú multivírus CTL-ek elõállítására |
SG11201407819UA (en) * | 2012-06-11 | 2014-12-30 | Wolf Wilson Mfg Corp | Improved methods of cell culture for adoptive cell therapy |
US11167024B2 (en) | 2015-09-18 | 2021-11-09 | Baylor College Of Medicine | Immunogenic antigen identification from a pathogen and correlation to clinical efficacy |
KR101867942B1 (ko) * | 2015-10-22 | 2018-06-20 | 가톨릭대학교 산학협력단 | 바이러스 항원 특이적인 t 세포의 유도 및 증식 방법 |
WO2017203370A2 (en) * | 2016-05-23 | 2017-11-30 | The Council Of The Queensland Institute Of Medical Research | Cmv epitopes |
EP3484525A4 (en) * | 2016-07-18 | 2020-07-29 | The Council of the Queensland Institute of Medical Research | MULTIVIRUS-SPECIFIC T-LYMPHOCYTES IMMUNOTHERAPY |
CA3036966A1 (en) * | 2016-09-16 | 2018-03-22 | Baylor College Of Medicine | Platform for activation and expansion of virus-specific t-cells |
US10821134B2 (en) | 2017-05-17 | 2020-11-03 | Board Of Regents, The University Of Texas System | BK virus specific T cells |
US10772914B1 (en) * | 2019-04-18 | 2020-09-15 | Baylor College Of Medicine | EBV-specific immune cells |
WO2020243729A1 (en) * | 2019-05-31 | 2020-12-03 | Children's National Medical Center | Cytokine cocktails for selective expansion of t cell subsets |
WO2021034674A1 (en) | 2019-08-16 | 2021-02-25 | Baylor College Of Medicine | Third party virus-specific t cell compositions, and methods of making and using the same in anti-viral prophylaxis |
EP4061386A4 (en) * | 2019-11-19 | 2024-01-10 | Acibadem Labmed Saglik Hizmetleri Anonim Sirketi | METHOD FOR PRODUCING MULTIVIRUS-SPECIFIC T CELLS |
EP4081226A4 (en) * | 2019-12-23 | 2024-03-27 | Baylor College of Medicine | T-CELL PERFORMANCE TEST AS A PROGNOSTIC FACTOR FOR CLINICAL OUTCOME |
JP2023518792A (ja) | 2020-03-20 | 2023-05-08 | ベイラー カレッジ オブ メディスン | SARS-CoV2特異的T細胞組成物ならびにコロナウイルスおよび他の呼吸器系ウイルス感染症の処置および予防におけるそれらの使用 |
CN113564116B (zh) * | 2021-07-21 | 2023-08-01 | 北京赛傲生物技术有限公司 | 特异性抗病毒过继免疫细胞ce的制备方法 |
WO2023224599A1 (en) | 2022-05-16 | 2023-11-23 | Allovir, Inc. | Multivirus-specific t cell compositions and their use in treating or preventing viral infection or disease in solid organ transplant recipients |
WO2023225485A1 (en) | 2022-05-16 | 2023-11-23 | Allovir, Inc. | Multivirus-specific t cell compositions and their use in treating or preventing viral infection or disease in solid organ transplant recipients |
Family Cites Families (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5641628A (en) | 1989-11-13 | 1997-06-24 | Children's Medical Center Corporation | Non-invasive method for isolation and detection of fetal DNA |
AU4678993A (en) | 1992-07-16 | 1994-02-14 | Board Of Trustees Of The Leland Stanford Junior University | Methods for using dendritic cells to activate t cells |
US6821778B1 (en) | 1993-12-01 | 2004-11-23 | The Board Of Trustees Of Leland Stanford Junior University | Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells |
PT749323E (pt) | 1994-03-08 | 2001-05-31 | Dana Farber Cancer Inst Inc | Metodos para modular a anergia das celulas t |
AUPM446594A0 (en) | 1994-03-16 | 1994-04-14 | Csl Limited | Cytotoxic t-cell epitopes identified within epstein-barr virus |
EP0772624B1 (en) | 1994-04-06 | 2000-09-13 | Immunex Corporation | Interleukin-15 |
AU691501B2 (en) | 1994-05-16 | 1998-05-21 | Boehringer Mannheim Gmbh | Method of immunomodulation by means of adoptive transfer of antigen-specific cytotoxic T-cells |
US6300090B1 (en) | 1994-07-29 | 2001-10-09 | The Rockefeller University | Methods of use of viral vectors to deliver antigen to dendritic cells |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
DE69618080T2 (de) | 1995-06-06 | 2002-06-13 | Organon Teknika B.V., Boxtel | Epstein-Barr Viruspeptide, und Antikörper gegen diese Peptide |
FR2745185B1 (fr) | 1996-02-28 | 1998-05-15 | Sanofi Sa | Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant |
US6699477B2 (en) | 1996-05-24 | 2004-03-02 | The Council Of The Queensland Institute Of Medical Research | EBV CTL epitopes |
US5962318A (en) | 1996-11-15 | 1999-10-05 | St. Jude Children's Research Hospital | Cytotoxic T lymphocyte-mediated immunotherapy |
JP2001509677A (ja) | 1997-01-31 | 2001-07-24 | エピミューン,インコーポレイティド | Ctlを活性化するためのペプチドおよびペプチド担持抗原提示細胞 |
US6528307B1 (en) | 1997-04-25 | 2003-03-04 | The Wistar Institute Of Anatomy And Biology | Cytolytic T-cell clones against colorectal carcinoma |
US7951383B2 (en) | 1997-05-23 | 2011-05-31 | The United States Of America As Represented By The Department Of Health And Human Services | Attenuated parainfluenza virus (PIV) vaccines |
AUPO784197A0 (en) | 1997-07-10 | 1997-08-07 | Csl Limited | Treatment of nasopharyngeal carcinoma |
US6274378B1 (en) | 1997-10-27 | 2001-08-14 | The Rockefeller University | Methods and compositions for obtaining mature dendritic cells |
US20020155108A1 (en) | 1998-05-04 | 2002-10-24 | Biocrystal, Ltd. | Method for ex vivo loading of antigen presenting cells with antigen, and a vaccine comprising the loaded cells |
EP1155115A4 (en) | 1999-02-24 | 2002-03-27 | Wistar Inst | MODIFICATION METHOD FOR CYTOTOXIC CELLS AND USES THEREOF |
US6828147B1 (en) | 1999-02-24 | 2004-12-07 | The Wistar Institute Of Anatomy And Biology | Method of modifying cytotoxic cells and uses thereof |
US7005131B1 (en) | 1999-08-13 | 2006-02-28 | The Rockefeller University | Protective antigen of Epstein Barr Virus |
US20150037297A1 (en) | 1999-08-30 | 2015-02-05 | David S Terman | Sickled Erythrocytes and Progenitors Target Cytotoxics to Tumors |
EP1231840B1 (en) | 1999-11-24 | 2009-07-22 | Ernest G. Hope | Anti-angiogenic cellular agent for cancer therapy |
DE10009341A1 (de) | 2000-02-22 | 2001-09-06 | Florian Kern | Verfahren zur antigen-spezifischen Stimulation von T-Lymphozyten |
US20020155127A1 (en) | 2000-06-02 | 2002-10-24 | Danher Wang | Genetic vaccine against human immunodeficiency virus |
US20020164331A1 (en) | 2000-06-19 | 2002-11-07 | Exley Mark A. | Compositions and methods of monoclonal and polyclonal antibodies specific for T cell subpopulations |
CA2422454A1 (en) | 2000-09-15 | 2002-03-21 | Ortho-Mcneil Pharmaceutical, Inc. | Compositions and methods for inducing specific cytolytic t cell responses |
EP1229043A1 (en) | 2001-01-30 | 2002-08-07 | Cyto-Barr B.V. | Peptides derived from Epstein Barr virus (EBV) proteins LMP1, LMP2 and BARF1 antibody reagents reactive therewith |
GB0107628D0 (en) | 2001-03-27 | 2001-05-16 | Avidex Ltd | Substances |
US20040022761A1 (en) | 2001-05-11 | 2004-02-05 | Banchereau Jacques F | Compositions and methods for producing antigen-presenting cells |
WO2002092773A2 (en) | 2001-05-15 | 2002-11-21 | Ortho-Mcneil Pharmaceutical, Inc. | Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease |
ES2255574T3 (es) | 2001-09-28 | 2006-07-01 | Heinrich-Gunter Schumacher | Cuchilla de segado con una guia de cuchilla co0nstituida por guias parciales. |
WO2003042377A1 (en) | 2001-11-07 | 2003-05-22 | Kirin Beer Kabushiki Kaisha | Expansion of t cells in vitro and expanded t cell populations |
US20030148982A1 (en) | 2001-11-13 | 2003-08-07 | Brenner Malcolm K. | Bi-spcific chimeric T cells |
AU2002365291B2 (en) | 2001-11-29 | 2007-11-01 | Dandrit Biotech A/S | Pharmaceutical composition for inducing an immune response in a human or animal |
US20040096457A1 (en) | 2001-12-11 | 2004-05-20 | Huber Brigitte T | Treatment and prevention of ebv infection and ebv-associated disorders |
US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
US7638325B2 (en) | 2002-01-03 | 2009-12-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform |
WO2004041849A1 (en) | 2002-11-07 | 2004-05-21 | The Council Of The Queensland Institute Of Medical Research | Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor |
AU2002953238A0 (en) | 2002-12-09 | 2003-01-02 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | In vitro immunization |
IL158140A0 (en) | 2003-09-25 | 2004-03-28 | Hadasit Med Res Service | Multiepitope polypeptides for cancer immunotherapy |
CA2542116C (en) | 2003-10-08 | 2015-01-27 | Wilson Wolf Manufacturing Corporation | Cell culture methods and devices utilizing gas permeable materials |
US20050221481A1 (en) | 2004-03-30 | 2005-10-06 | Istituto Superiore Di Sanita' | Amplification of T cells from human cord blood in serum-deprived culture stimulated with stem cell factor, interleukin-7 and interleukin-2 |
US7785806B2 (en) | 2004-04-28 | 2010-08-31 | Vaxdesign Corporation | Method for determining the immunogenicity of an antigen |
JP5070045B2 (ja) | 2004-05-27 | 2012-11-07 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 新規人工抗原提示細胞およびそれらの用途 |
US7785875B2 (en) | 2004-07-03 | 2010-08-31 | Mogam Biotechnology Research Institute | Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same |
US20060045883A1 (en) | 2004-08-26 | 2006-03-02 | Jeffrey Molldrem | Anti-cancer vaccines |
JP4731867B2 (ja) | 2004-10-01 | 2011-07-27 | 国立大学法人三重大学 | Cd8陽性の細胞傷害性tリンパ球の誘導方法 |
US20060204509A1 (en) | 2005-03-14 | 2006-09-14 | Harty John T | Accelerated CD8+ T-cell memory after dendritic cell vaccination |
EP1712615A1 (en) | 2005-04-15 | 2006-10-18 | Txcell | In vitro production of a cell population using feeder cells |
ES2334936T3 (es) | 2005-04-20 | 2010-03-17 | F. Hoffmann-La Roche Ag | Metodo de identificacion de epitopos relacionados con la inmunogenicidad en biofarmacos. |
JP2008539758A (ja) | 2005-05-11 | 2008-11-20 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 抗原特異的t−細胞の急速な増大のための方法 |
US20070003531A1 (en) | 2005-06-30 | 2007-01-04 | University Of Connecticut | Methods for improving immunotherapy by enhancing survival of antigen-specific cytotoxic T lymphocytes |
US20100035282A1 (en) | 2005-08-03 | 2010-02-11 | Maria Chiara Bonini | Use of common gamma chain cytokines for the visualization, isolation and genetic modification of memory t lymphocytes |
JP4824389B2 (ja) * | 2005-10-28 | 2011-11-30 | 株式会社医学生物学研究所 | エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性t細胞エピトープペプチド及びその用途 |
CA2630218A1 (en) | 2005-11-18 | 2007-08-30 | The Ohio State University Research Foundation | Viral gene products and methods for vaccination to prevent viral associated diseases |
ATE514081T1 (de) | 2006-03-02 | 2011-07-15 | Antitope Ltd | T-zellen-testverfahren |
GB0604170D0 (en) | 2006-03-02 | 2006-04-12 | Antitope Ltd | T cell assays |
WO2007121276A2 (en) | 2006-04-12 | 2007-10-25 | Biocept, Inc. | Enrichment of circulating fetal dna |
WO2008025992A2 (en) | 2006-09-01 | 2008-03-06 | Cambridge Enterprise Limited | Methods of expanding non-effector cd8 t-cell populations |
US7846446B2 (en) | 2006-11-22 | 2010-12-07 | Board Of Trustees Of The University Of Arkansas | Multi-epitope peptide-loaded dendritic cell immunotherapy for cancer |
US20080176318A1 (en) | 2006-12-07 | 2008-07-24 | Wilson John R | Highly efficient devices and methods for culturing cells |
JP2010512324A (ja) | 2006-12-08 | 2010-04-22 | アッテヌオン エル エル シー | ウロキナーゼ型プラスミノーゲン活性化因子受容体エピトープ、それに由来するモノクローナル抗体及びそれらの使用方法 |
DE102006060824B4 (de) | 2006-12-21 | 2011-06-01 | Johannes-Gutenberg-Universität Mainz | Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten |
WO2009042215A2 (en) | 2007-09-27 | 2009-04-02 | The Board Of Trustees Of The University Of Arkansas | Inhibition of dendritic cell-driven regulatory t cell activation and potentiation of tumor antigen-specific t cell responses by interleukin-15 and map kinase inhibitor |
EP2060583A1 (en) | 2007-10-23 | 2009-05-20 | Ganymed Pharmaceuticals AG | Identification of tumor-associated markers for diagnosis and therapy |
WO2009053109A1 (en) | 2007-10-24 | 2009-04-30 | Anne Letsch | Antigen-specific t-cell preparations from bone marrow |
CN102066410B (zh) | 2007-11-01 | 2017-01-18 | 梅约医学教育与研究基金会 | Hla‑dr结合肽和它们的应用 |
EP2065462A1 (en) | 2007-11-27 | 2009-06-03 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens |
CA2736851A1 (en) | 2008-09-11 | 2010-03-18 | Lung-Ji Chang | System and method for producing t cells |
CN101824400B (zh) | 2009-03-05 | 2012-08-08 | 中国科学院微生物研究所 | 一种放大增殖抗原特异性t细胞的方法 |
CN102625832A (zh) | 2009-08-24 | 2012-08-01 | 贝勒医学院 | 产生对多种肿瘤抗原或多种病毒特异的ctl细胞系 |
JP5833443B2 (ja) | 2009-08-29 | 2015-12-16 | 株式会社バイオメッドコア | 抗原特異的t細胞誘導能測定法 |
GB0917090D0 (en) | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
US20130115617A1 (en) | 2009-12-08 | 2013-05-09 | John R. Wilson | Methods of cell culture for adoptive cell therapy |
SG181559A1 (en) | 2009-12-08 | 2012-07-30 | Wolf Wilson Mfg Corp | Improved methods of cell culture for adoptive cell therapy |
US8956860B2 (en) | 2009-12-08 | 2015-02-17 | Juan F. Vera | Methods of cell culture for adoptive cell therapy |
US9115402B2 (en) | 2010-05-14 | 2015-08-25 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of identifying tumor specific neoantigens |
WO2011146473A1 (en) | 2010-05-17 | 2011-11-24 | Duke University | Methods of treatment using ex vivo expansion of cord blood t cells |
US20130129713A1 (en) | 2010-08-04 | 2013-05-23 | Ieo - Istituto Europeo Di Oncologia S.R.L. | Method of antigen loading for immunotherapy |
WO2012054792A2 (en) | 2010-10-22 | 2012-04-26 | Virginia Commonwealth University | Composition and method for immunological treatment of cancer, prevention of cancer recurrence and metastasis, and overcoming immune suppressor cells |
EP2453243A1 (en) | 2010-11-11 | 2012-05-16 | Cosmo S.p.A. | Method for the diagnosis and/or follow up of the evolution of a tumor |
US20130045491A1 (en) | 2011-07-19 | 2013-02-21 | Derya Unutmaz | Methods for activating t cells |
WO2013035099A1 (en) | 2011-09-08 | 2013-03-14 | Yeda Research And Development Co. Ltd. | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
JP6081483B2 (ja) | 2011-12-12 | 2017-02-15 | セル・メディカ・リミテッド | T細胞を増殖させるプロセス |
HUE060369T2 (hu) | 2012-02-09 | 2023-02-28 | Baylor College Medicine | Peptidkeverékek széles spektrumú multivírus CTL-ek elõállítására |
US20130217122A1 (en) | 2012-02-21 | 2013-08-22 | The Trustees Of The University Of Pennsylvania | Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library |
US9943578B2 (en) | 2012-05-08 | 2018-04-17 | Western University Of Health Sciences | Standardized ex vivo platforms for the antigen-specific expansion of CD4+ T cell populations |
EP3071686B1 (en) | 2013-11-22 | 2020-07-22 | Cellectis SA | Method for generating batches of allogeneic t-cells with averaged potency |
US20160341718A1 (en) | 2014-01-21 | 2016-11-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for testing t cell priming efficacy in a subject |
CA2966351A1 (en) | 2014-11-05 | 2016-05-12 | Memorial Sloan Kettering Cancer Center | Methods of selecting t cell line and donor thereof for adoptive cellular therapy |
WO2016073595A1 (en) | 2014-11-05 | 2016-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | T cells and dendritic cells for polyomavirus therapy |
AU2016235388B2 (en) | 2015-03-20 | 2022-02-03 | Children's National Medical Center | Generating virus or other antigen-specific T cells from a naive T cell population |
EP3313419B1 (en) | 2015-06-26 | 2020-08-19 | Memorial Sloan Kettering Cancer Center | Methods of treating cmv retinitis by t cell therapy |
US11167024B2 (en) | 2015-09-18 | 2021-11-09 | Baylor College Of Medicine | Immunogenic antigen identification from a pathogen and correlation to clinical efficacy |
KR20230113817A (ko) | 2016-05-25 | 2023-08-01 | 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 | 동종이계 t 세포를 이용한 자가면역 질환을 치료하는방법 |
KR20190037243A (ko) | 2016-06-28 | 2019-04-05 | 지니우스 바이오테크놀로지 인코포레이티드 | 면역치료를 위한 티 세포 조성물 |
CA3036966A1 (en) | 2016-09-16 | 2018-03-22 | Baylor College Of Medicine | Platform for activation and expansion of virus-specific t-cells |
US20200172864A1 (en) | 2016-09-26 | 2020-06-04 | Tessa Therapeutics Ltd. | T Cell Expansion Method |
US11951127B2 (en) | 2017-06-22 | 2024-04-09 | The Westmead Institute for Medical Research | Adoptive T cell therapy 2 |
US11646103B2 (en) | 2017-09-06 | 2023-05-09 | Nant Holdings Ip, Llc | HLA tissue matching and methods therefor |
GB201808651D0 (en) | 2018-05-25 | 2018-07-11 | Rolls Royce Plc | Rotor blade arrangement |
BR112021019120A2 (pt) | 2019-03-25 | 2021-11-30 | Baylor College Medicine | Células t específicas para antígenos de múltiplos vírus respiratórios e métodos de produção e uso das mesmas terapeuticamente |
TWI777160B (zh) | 2019-05-08 | 2022-09-11 | 美商百歐恩泰美國公司 | T細胞製備組合物及方法 |
MA56534A (fr) | 2019-06-20 | 2022-04-27 | Janssen Sciences Ireland Unlimited Co | Administration par nanoporteurs glucidiques, de vaccins contre le virus de l'hépatite b (vhb) |
US20220257654A1 (en) | 2019-07-23 | 2022-08-18 | Baylor College Of Medicine | Antigen-specific t cell banks and methods of making and using the same therapeutically |
MX2022001322A (es) | 2019-07-29 | 2022-05-24 | Baylor College Medicine | Bancos de células t específicas de antígeno y métodos para fabricar y usar los mismos terapéuticamente. |
WO2021034674A1 (en) | 2019-08-16 | 2021-02-25 | Baylor College Of Medicine | Third party virus-specific t cell compositions, and methods of making and using the same in anti-viral prophylaxis |
EP4081226A4 (en) | 2019-12-23 | 2024-03-27 | Baylor College of Medicine | T-CELL PERFORMANCE TEST AS A PROGNOSTIC FACTOR FOR CLINICAL OUTCOME |
JP2023518792A (ja) | 2020-03-20 | 2023-05-08 | ベイラー カレッジ オブ メディスン | SARS-CoV2特異的T細胞組成物ならびにコロナウイルスおよび他の呼吸器系ウイルス感染症の処置および予防におけるそれらの使用 |
EP3974029A1 (en) | 2020-09-25 | 2022-03-30 | Universidad Autónoma de Madrid | Memory t cells as adoptive cell therapy for viral infections |
WO2023159088A1 (en) | 2022-02-15 | 2023-08-24 | Marker Therapeutics, Inc. | Compositions and methods for antigen-specific t cell expansion |
-
2013
- 2013-02-08 HU HUE19178235A patent/HUE060369T2/hu unknown
- 2013-02-08 ES ES19178235T patent/ES2928851T3/es active Active
- 2013-02-08 ES ES13746524T patent/ES2748652T3/es active Active
- 2013-02-08 EP EP19178235.8A patent/EP3591047B1/en active Active
- 2013-02-08 EP EP13746524.1A patent/EP2812431B1/en active Active
- 2013-02-08 US US14/377,825 patent/US20150010519A1/en not_active Abandoned
- 2013-02-08 HR HRP20221303TT patent/HRP20221303T1/hr unknown
- 2013-02-08 PT PT137465241T patent/PT2812431T/pt unknown
- 2013-02-08 PL PL19178235.8T patent/PL3591047T3/pl unknown
- 2013-02-08 DK DK19178235.8T patent/DK3591047T3/da active
- 2013-02-08 WO PCT/US2013/025342 patent/WO2013119947A1/en active Application Filing
- 2013-02-08 PL PL13746524T patent/PL2812431T3/pl unknown
- 2013-02-08 PT PT191782358T patent/PT3591047T/pt unknown
- 2013-02-08 DK DK13746524.1T patent/DK2812431T3/da active
- 2013-02-08 EP EP22166731.4A patent/EP4089167A1/en active Pending
-
2018
- 2018-02-26 US US15/905,176 patent/US11118164B2/en active Active
-
2021
- 2021-07-23 US US17/443,261 patent/US20210348127A1/en active Pending
-
2022
- 2022-04-18 US US17/659,624 patent/US11981923B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
PL3591047T3 (pl) | 2022-12-05 |
HRP20221303T1 (hr) | 2022-12-23 |
EP2812431B1 (en) | 2019-07-17 |
EP2812431A1 (en) | 2014-12-17 |
EP2812431A4 (en) | 2015-08-19 |
ES2748652T3 (es) | 2020-03-17 |
DK3591047T3 (da) | 2022-10-24 |
HUE060369T2 (hu) | 2023-02-28 |
EP3591047B1 (en) | 2022-08-03 |
US11981923B2 (en) | 2024-05-14 |
US20150010519A1 (en) | 2015-01-08 |
EP3591047A1 (en) | 2020-01-08 |
ES2928851T3 (es) | 2022-11-23 |
US20220251508A1 (en) | 2022-08-11 |
EP4089167A1 (en) | 2022-11-16 |
PT3591047T (pt) | 2022-10-20 |
US11118164B2 (en) | 2021-09-14 |
PL2812431T3 (pl) | 2020-02-28 |
WO2013119947A1 (en) | 2013-08-15 |
US20180187152A1 (en) | 2018-07-05 |
US20210348127A1 (en) | 2021-11-11 |
DK2812431T3 (da) | 2019-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL277912B (en) | Intentional healing | |
EP2812431A4 (en) | MIXTURE OF PEPTIDES FOR PRODUCING CTLMULTIVIRALS WITH LARGE SPECIFICITY | |
HK1209762A1 (en) | Targeted therapeutics | |
SG11201405573WA (en) | Production of graphene | |
EP2932375A4 (en) | ADAPTATION OF OPPORTUNITY IN CONTEXT | |
HK1202051A1 (en) | Erythrocyte-binding therapeutics | |
EP2815546A4 (en) | CONSTRUCTION OF A LARGE SCALE DVPN | |
ZA201406082B (en) | Use of ccr3-inhibitors | |
EP2898114A4 (en) | HYDROGEN PRODUCTION | |
GB201118302D0 (en) | Improvements to tyres | |
GB201306740D0 (en) | Improvements relating to locking apparartus | |
IL235544A0 (en) | Conversion of propane to propylene | |
EP2892529A4 (en) | USES OF (-) - PERHEXILINE | |
GB2507762B (en) | Improvements to dartboards | |
GB201213110D0 (en) | Improvement to urinals | |
GB201216223D0 (en) | Improvements to travelling holgrams | |
GB201205082D0 (en) | Further graphene developments | |
GB201200029D0 (en) | Secure as you go | |
GB201215288D0 (en) | Improvements relating to firelighters | |
GB201213907D0 (en) | Fast prostaglandin reduction | |
TWM433525U (en) | Structure of calorifier | |
GB201217794D0 (en) | Improvements to social alarms | |
GB201214597D0 (en) | Super reggae man | |
GB201211195D0 (en) | Improvements to social alarms | |
GB201207048D0 (en) | Improvements to social alarms |